$MEIP
MEI Pharma, Inc.

2013 Q4 Form 10-Q Financial Statement

#000119312513433915 Filed on November 08, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.950M $1.810M $910.0K
YoY Change 37.32% 98.9% 2.25%
% of Gross Profit
Research & Development $4.400M $3.102M $1.552M
YoY Change 228.85% 99.87% 48.66%
% of Gross Profit
Depreciation & Amortization $10.00K $13.00K $8.000K
YoY Change 0.0% 62.5% 166.67%
% of Gross Profit
Operating Expenses $6.349M $4.913M $2.466M
YoY Change 130.37% 99.23% 27.57%
Operating Profit -$6.349M -$4.913M -$2.466M
YoY Change 130.37% 99.23% 27.57%
Interest Expense $30.00K $20.00K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.320M -$4.900M -$2.460M
YoY Change 129.82% 99.19% 52.8%
Income Tax $0.00 $1.000K $1.000K
% Of Pretax Income
Net Earnings -$6.324M -$4.896M -$2.464M
YoY Change 129.63% 98.7% 52.85%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$314.9K -$286.2K -$702.9K
COMMON SHARES
Basic Shares Outstanding 21.49M shares 17.12M shares 21.67M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.80M $31.50M $3.700M
YoY Change 122.3% 751.35% -22.92%
Cash & Equivalents $39.76M $31.50M $3.713M
Short-Term Investments $20.00M
Other Short-Term Assets $900.0K $600.0K $100.0K
YoY Change 350.0% 500.0% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $60.66M $32.11M $3.836M
YoY Change 124.04% 736.97% -21.71%
LONG-TERM ASSETS
Property, Plant & Equipment $46.00K $50.00K $23.00K
YoY Change 109.09% 117.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $499.0K $511.0K $519.0K
YoY Change -2.16% -1.54%
TOTAL ASSETS
Total Short-Term Assets $60.66M $32.11M $3.836M
Total Long-Term Assets $499.0K $511.0K $519.0K
Total Assets $61.16M $32.62M $4.355M
YoY Change 121.7% 648.96% -11.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $809.0K $557.0K $533.0K
YoY Change 80.58% 4.5% 77.67%
Accrued Expenses $1.619M $908.0K $1.097M
YoY Change 20.01% -17.23% 37.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.428M $1.465M $1.630M
YoY Change 35.11% -10.12% 1.88%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.428M $1.465M $1.630M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.400M $1.500M $1.600M
YoY Change 33.33% -6.25% 0.0%
SHAREHOLDERS EQUITY
Retained Earnings -$107.5M -$101.2M -$87.58M
YoY Change 19.03% 15.55%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $58.73M $31.15M $2.725M
YoY Change
Total Liabilities & Shareholders Equity $61.16M $32.62M $4.355M
YoY Change 121.7% 648.96% -11.12%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$6.324M -$4.896M -$2.464M
YoY Change 129.63% 98.7% 52.85%
Depreciation, Depletion And Amortization $10.00K $13.00K $8.000K
YoY Change 0.0% 62.5% 166.67%
Cash From Operating Activities -$4.470M -$4.063M -$2.487M
YoY Change 106.94% 63.37% 43.76%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $6.000K $2.000K
YoY Change 200.0%
Acquisitions
YoY Change
Other Investing Activities -$20.00M
YoY Change
Cash From Investing Activities -$20.00M -$6.000K -$2.000K
YoY Change 200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 32.73M 0.000 0.000
YoY Change 29.21% -100.0%
NET CHANGE
Cash From Operating Activities -4.470M -4.063M -2.487M
Cash From Investing Activities -20.00M -6.000K -2.000K
Cash From Financing Activities 32.73M 0.000 0.000
Net Change In Cash 8.260M -4.069M -2.489M
YoY Change -64.35% 63.48% -364.23%
FREE CASH FLOW
Cash From Operating Activities -$4.470M -$4.063M -$2.487M
Capital Expenditures $0.00 $6.000K $2.000K
Free Cash Flow -$4.470M -$4.069M -$2.489M
YoY Change 106.94% 63.48% 43.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21493405 shares
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3713000
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17116662 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
183841 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.98
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
960449 shares
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.56
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17116662 shares
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1465000
CY2013Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
132345000
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
557000
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
31152000
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101193000
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
908000
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32617000
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3896000
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50000
CY2013Q3 us-gaap Assets
Assets
32617000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31504000
CY2013Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
461000
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
603000
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3517000
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
602000
CY2013Q3 us-gaap Assets Current
AssetsCurrent
32106000
CY2013Q3 meip Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y2M12D
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6202000
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17116571 shares
CY2013Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.26
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
635094 shares
CY2013Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17116571 shares
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1675000
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
131169000
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
537000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
34872000
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96297000
CY2013Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1138000
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36547000
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
48000
CY2013Q2 us-gaap Assets
Assets
36547000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35573000
CY2013Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
470000
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1934000
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
456000
CY2013Q2 us-gaap Assets Current
AssetsCurrent
36029000
CY2013Q2 meip Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y1M6D
CY2012Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-6
CY2012Q3 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
195756 shares
CY2000Q4 meip Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2000-12
CY2012Q3 meip Agreement Termination Notice Period
AgreementTerminationNoticePeriod
P90D
CY2012Q3 meip Percentage Of Purchases From Major Suppliers
PercentageOfPurchasesFromMajorSuppliers
1.00 pure
CY2012Q3 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
500000
CY2012Q3 meip Upfront And Milestone Payments
UpfrontAndMilestonePayments
200000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-95047000
us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
500000 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
95000
us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
1188000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
2954000
us-gaap Profit Loss
ProfitLoss
-101193000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
602000
us-gaap Gain Loss On Investments
GainLossOnInvestments
100000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
406000
us-gaap Operating Income Loss
OperatingIncomeLoss
-104509000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-508000
us-gaap Financial Services Costs
FinancialServicesCosts
406000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29719000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
126646000
us-gaap Share Based Compensation
ShareBasedCompensation
5473000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
31504000
us-gaap Operating Expenses
OperatingExpenses
104509000
us-gaap License Costs
LicenseCosts
21500000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
557000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
908000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
126387000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
84000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-95000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53290000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
665000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.53 pure
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.7100 pure
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3499475 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.76
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2012Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2487000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0064 pure
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1938294 shares
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.55 pure
CY2012Q3 us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
500000 shares
CY2012Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
CY2012Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
3000
CY2012Q3 us-gaap Profit Loss
ProfitLoss
-2464000
CY2012Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-23000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2466000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
914000
CY2012Q3 us-gaap Share Based Compensation
ShareBasedCompensation
90000
CY2012Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2489000
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
2466000
CY2012Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-61000
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2012Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-83000
CY2012Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8000
CY2012Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1552000
CY2013Q3 dei Trading Symbol
TradingSymbol
MEIP
CY2013Q3 dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
CY2013Q3 dei Amendment Flag
AmendmentFlag
false
CY2013Q3 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2013Q3 dei Document Type
DocumentType
10-Q
CY2013Q3 dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
CY2013Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001262104
CY2013Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2013Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.56 pure
CY2013Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.39
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0160 pure
CY2013Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P14Y
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17116611 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.68
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4063000
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0140 pure
CY2013Q3 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>Concentration of Credit Risk</b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 8%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains accounts in federally insured financial institutions in excess of federally insured limits. However, management believes that the Company is not exposed to significant credit risk due to the financial positions of the depository institutions in which these deposits are held.</p> </div>
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.00
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6421590 shares
CY2013Q3 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>Use of Estimates</b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 8%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. The Company uses estimates for certain accruals including clinical and pre-clinical study fees and expenses, share-based compensation, and valuations of derivative liabilities, among others. Actual results could differ from those estimates.</p> </div>
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
325355 shares
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y4M24D
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.58 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y
CY2013Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2013Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
18000
CY2013Q3 us-gaap Profit Loss
ProfitLoss
-4896000
CY2013Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
146000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4913000
CY2013Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1811000
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1176000
CY2013Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4069000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
4913000
CY2013Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
20000
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2013Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-230000
CY2013Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13000
CY2013Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3102000
CY2013Q3 meip Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
P4Y9M18D
CY2013Q3 meip Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue
1583000
CY2013Q3 meip Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodTotalIntrinsicValue
CY2013Q3 meip Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2015-06
CY2013Q3 meip Lease Arrangement Rent Area
LeaseArrangementRentArea
6200 sqft
CY2013Q3 meip Percentage Of Likelihood Of Income Tax Being Sustained
PercentageOfLikelihoodOfIncomeTaxBeingSustained
0.50 pure
CY2013Q3 meip Cash And Cash Equivalent Maturity Period Maximum
CashAndCashEquivalentMaturityPeriodMaximum
P3M

Files In Submission

Name View Source Status
0001193125-13-433915-index-headers.html Edgar Link pending
0001193125-13-433915-index.html Edgar Link pending
0001193125-13-433915.txt Edgar Link pending
0001193125-13-433915-xbrl.zip Edgar Link pending
d606497d10q.htm Edgar Link pending
d606497dex311.htm Edgar Link pending
d606497dex312.htm Edgar Link pending
d606497dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
meip-20130930.xml Edgar Link completed
meip-20130930.xsd Edgar Link pending
meip-20130930_cal.xml Edgar Link unprocessable
meip-20130930_def.xml Edgar Link unprocessable
meip-20130930_lab.xml Edgar Link unprocessable
meip-20130930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending